Cargando…

Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines

In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. Howev...

Descripción completa

Detalles Bibliográficos
Autores principales: Hannani, Dalil, Leplus, Estelle, Laulagnier, Karine, Chaperot, Laurence, Plumas, Joël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886307/
https://www.ncbi.nlm.nih.gov/pubmed/36726965
http://dx.doi.org/10.18632/genesandcancer.229
_version_ 1784880107671781376
author Hannani, Dalil
Leplus, Estelle
Laulagnier, Karine
Chaperot, Laurence
Plumas, Joël
author_facet Hannani, Dalil
Leplus, Estelle
Laulagnier, Karine
Chaperot, Laurence
Plumas, Joël
author_sort Hannani, Dalil
collection PubMed
description In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity. There is therefore a need to boost the frequency and function of patients’ cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured. Here we discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells.
format Online
Article
Text
id pubmed-9886307
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-98863072023-01-31 Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines Hannani, Dalil Leplus, Estelle Laulagnier, Karine Chaperot, Laurence Plumas, Joël Genes Cancer Research Perspective In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity. There is therefore a need to boost the frequency and function of patients’ cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured. Here we discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells. Impact Journals LLC 2023-01-30 /pmc/articles/PMC9886307/ /pubmed/36726965 http://dx.doi.org/10.18632/genesandcancer.229 Text en https://creativecommons.org/licenses/by/3.0/Copyright: © 2023 Hannani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Perspective
Hannani, Dalil
Leplus, Estelle
Laulagnier, Karine
Chaperot, Laurence
Plumas, Joël
Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
title Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
title_full Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
title_fullStr Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
title_full_unstemmed Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
title_short Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
title_sort leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines
topic Research Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9886307/
https://www.ncbi.nlm.nih.gov/pubmed/36726965
http://dx.doi.org/10.18632/genesandcancer.229
work_keys_str_mv AT hannanidalil leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines
AT leplusestelle leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines
AT laulagnierkarine leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines
AT chaperotlaurence leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines
AT plumasjoel leveragingapowerfulallogeneicdendriticcelllinetowardsneoantigenbasedcancervaccines